{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:44:00Z","timestamp":1791297840266,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,12,26]],"date-time":"2012-12-26T00:00:00Z","timestamp":1356480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:p>Tetrabenazine is effective in the treatment of the chorea associated with Huntington disease and other hyperkinetic movement disorders. Following oral administration, tetrabenazine is hepatically transformed into 2 active metabolites that are <jats:styled-content style=\"fixed-case\">CYP2D6<\/jats:styled-content> substrates. There are 4 <jats:styled-content style=\"fixed-case\">CYP2D6<\/jats:styled-content> genotypes: poor metabolizers, intermediate metabolizers, extensive metabolizers, and ultrarapid metabolizers. <jats:styled-content style=\"fixed-case\">CYP2D6<\/jats:styled-content> genotyping was performed on sequential subjects treated with tetrabenazine, but results were not known at the time of titration. Duration of titration to a stable dose, total daily dose, response rating scores, and adverse events were retrospectively collected and subsequently analyzed. Of 127 patients, the majority (n = 100) were categorized as extensive metabolizers, 14 as intermediate metabolizers, 11 as poor metabolizers, and 2 as ultrarapid metabolizers. Ultrarapid metabolizer patients needed a longer titration (8 vs 3.3, 4.4, and 3 weeks, respectively; <jats:italic>P<\/jats:italic> &lt; .01) to achieve optimal benefit and required a higher average daily dose than the other patients, but this difference did not reach statistical significance. The treatment response was less robust in the intermediate metabolizer group when compared with the extensive metabolizer patients (<jats:italic>P<\/jats:italic> = .013), but there were no statistically significant differences between the various groups with regard to adverse effects. Our findings demonstrate that, aside from the need for a longer titration in the ultrarapid metabolizers, there are no distinguishing features of patients with various <jats:styled-content style=\"fixed-case\">CYP2D6<\/jats:styled-content> genotypes, and therefore the current recommendation to systematically genotype all patients prescribed more than 50 mg\/day of tetrabenazine should be reconsidered. \u00a9 2012 <jats:italic>Movement<\/jats:italic> Disorder Society<\/jats:p>","DOI":"10.1002\/mds.25278","type":"journal-article","created":{"date-parts":[[2012,12,26]],"date-time":"2012-12-26T16:19:55Z","timestamp":1356538795000},"page":"210-215","source":"Crossref","is-referenced-by-count":47,"title":["Analysis of <i><scp>CYP2D6<\/scp><\/i> genotype and response to tetrabenazine"],"prefix":"10.1002","volume":"28","author":[{"given":"Raja","family":"Mehanna","sequence":"first","affiliation":[{"name":"Parkinson's Disease Center Movement Disorders Clinic Department of Neurology Baylor College of Medicine Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hunter","sequence":"additional","affiliation":[{"name":"Parkinson's Disease Center Movement Disorders Clinic Department of Neurology Baylor College of Medicine Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Davidson","sequence":"additional","affiliation":[{"name":"Parkinson's Disease Center Movement Disorders Clinic Department of Neurology Baylor College of Medicine Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohi","family":"Jimenez\u2010Shahed","sequence":"additional","affiliation":[{"name":"Parkinson's Disease Center Movement Disorders Clinic Department of Neurology Baylor College of Medicine Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[{"name":"Parkinson's Disease Center Movement Disorders Clinic Department of Neurology Baylor College of Medicine Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-9-62"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70183-8"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.6.1.7"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21063"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903386292"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.11.149"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22502"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732030-00004"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5439.487"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-003-0819-z"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600760610"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.2.358"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.02.007"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.50"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)20152-5"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(99)01363-2"},{"key":"e_1_2_6_19_1","unstructured":"Xenazine package insert Lundbeck Deerfield IL."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020021"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100455"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1010600"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2010.11.003"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2009.14"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2010.08.006"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9313-6"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.NPR.0000405282.67906.a8"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.54"},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","unstructured":"RaeJM DruryS HayesDF et al.Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. 33rd Annual San Antonio Breast Cancer Symposium. Abstract S1\u20137. Presented December 9 2010.","DOI":"10.1158\/0008-5472.SABCS10-S1-7"},{"key":"e_1_2_6_30_1","doi-asserted-by":"crossref","unstructured":"Leyland\u2010JonesB ReganMM BouzkM et al.Outcome according to CYP2D6 genotype among postmenopausal women with endocrine\u2010responsive early invasive breast cancer randomized in the BIG 1\u201398 trial. 33rd Annual San Antonio Breast Cancer Symposium. Abstract S1\u20138. Presented December 9 2010.","DOI":"10.1158\/0008-5472.SABCS10-S1-8"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008410"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1880"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1865"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta15330"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.08.003"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.20"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25278","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:30:35Z","timestamp":1760959835000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.25278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,26]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1002\/mds.25278"],"URL":"https:\/\/doi.org\/10.1002\/mds.25278","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,26]]}}}